# Bioray Laboratories clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Bioray Laboratories as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bioray Laboratories: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/bioray-laboratories

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 25, 2025 | NCT07248176 | Universal CAR-T Cell Therapy for MM | Bioray Laboratories | Not applicable | Recruiting | Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07248176) |
| November 25, 2025 | NCT07248163 | Universal CAR-T Cell Therapy for NHL | Bioray Laboratories | Not applicable | Recruiting | Non-hodgkin Lymphoma,B Cell | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07248163) |
| November 8, 2024 | NCT06681337 | Universal CAR-T Cell Therapy for Refractory Lupus Nephritis | Bioray Laboratories | Early phase 1 | Unknown | Lupus Nephritis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06681337) |
| October 9, 2024 | NCT06633042 | The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD | Bioray Laboratories | Phase 1 | Unknown | Autoimmune Disease | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06633042) |
| March 18, 2024 | NCT06314529 | Long-term Follow-up Study of BHC001 for TDT | Bioray Laboratories | Observational | Recruiting | Thalassemia, Beta | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06314529) |
| March 8, 2024 | NCT06300723 | Clinical Study of BRL-101 in Severe SCD | Bioray Laboratories | Not applicable | Unknown | Sickle Cell Disease | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06300723) |
| March 7, 2024 | NCT06298630 | Long-term Follow-up Study of BRL-101 for TDT | Bioray Laboratories | Observational | Recruiting | Thalassemia, Beta | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298630) |
| February 29, 2024 | NCT06287099 | Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease | Bioray Laboratories | Not applicable | Unknown | Sickle Cell Disease | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06287099) |
| February 29, 2024 | NCT06287086 | Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease | Bioray Laboratories | Not applicable | Unknown | Sickle Cell Disease | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06287086) |
| August 14, 2023 | NCT05988216 | Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus | Bioray Laboratories | Not applicable | Unknown | Systemic Lupus Erythematosus (SLE) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05988216) |
| May 16, 2023 | NCT05859997 | Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases | Bioray Laboratories | Not applicable | Enrolling by invitation | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05859997) |
| February 23, 2023 | NCT05741359 | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | Bioray Laboratories | Phase 1 | Recruiting | Non-hodgkin Lymphoma,B Cell | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05741359) |
| October 13, 2022 | NCT05577312 | Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia | Bioray Laboratories | Phase 1/2 | Active not recruiting | Beta-Thalassemia | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05577312) |
| July 5, 2022 | NCT05442346 | Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells | Bioray Laboratories | Not applicable | Suspended | Thalassemia Major | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05442346) |
| May 19, 2022 | NCT05381181 | Safety and Efficacy Evaluation of Next-generation CD19-UCART | Bioray Laboratories | Phase 1 | Unknown | Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05381181) |
| April 4, 2022 | NCT05308875 | Efficacy and Safety Evaluation of PD1-BCMA-CART | Bioray Laboratories | Not applicable | Unknown | Multiple Myeloma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05308875) |
| December 30, 2019 | NCT04213469 | PD1-CD19-CART in Patients With r/r B-cell Lymphoma | Bioray Laboratories | Not applicable | Completed | B-cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04213469) |
| December 26, 2019 | NCT04211480 | Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells | Bioray Laboratories | Not applicable | Completed | β Thalassemia Major | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04211480) |
| December 19, 2019 | NCT04205435 | β-globin Restored Autologous HSC in β-thalassemia Major Patients | Bioray Laboratories | Phase 1/2 | Terminated | β-thalassemia Major | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04205435) |
| August 12, 2019 | NCT04053062 | LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer | Bioray Laboratories | Phase 1 | Suspended | Castrate-Resistant Prostate Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04053062) |
| November 26, 2018 | NCT03752541 | Efficacy and Safety Evaluation of BCMA-UCART | Bioray Laboratories | Not applicable | Suspended | Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03752541) |
| April 10, 2018 | NCT03492268 | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | Bioray Laboratories | Not applicable | Withdrawn | Multiple Myeloma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03492268) |
| July 28, 2017 | NCT03232619 | CD19-CART Treatment for ALL | Bioray Laboratories | Phase 1/2 | Completed | Acute Leukemia | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03232619) |
| July 26, 2017 | NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | Bioray Laboratories | Not applicable | Suspended | Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03229876) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 4 |
| Phase 1/2 | 3 |
| Not applicable | 14 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 8 |
| Recruiting | 5 |
| Suspended | 4 |
| Completed | 3 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| beta-Thalassemia | 4 |
| Multiple Myeloma | 4 |
| Anemia, Sickle Cell | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Lymphoma, Non-Hodgkin | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Sjogren's Syndrome | 1 |
| Scleroderma, Systemic | 1 |
| Myositis | 1 |
| Antiphospholipid Syndrome | 1 |
| Lymphoma, B-Cell | 1 |
| Lupus Nephritis | 1 |
| Autoimmune Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Pediatric clinics in the United States](https://specstream.ai/data/businesses/pediatric-clinics/united-states)
- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Meat wholesalers in the United States](https://specstream.ai/data/businesses/meat-wholesalers/united-states)
- [Architecture firms in the United States](https://specstream.ai/data/businesses/architecture-firms/united-states)
- [Immunodermatology practices in the United States](https://specstream.ai/data/businesses/immunodermatology-practices/united-states)
